Drugs / Alvelestat
Trials 13 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT01214122 | Nov → Dec 2010 | — | AstraZeneca | Withdrawn | No outcome recorded |
| Phase 1 | NCT01161355 | Jun 2010 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01147549 | Jun → Jul 2010 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01035411 | Nov → Dec 2009 | chronic obstructive pulmonary disease | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01034982 | Nov → Dec 2009 | chronic obstructive pulmonary disease | AstraZeneca | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT03986086 | Sep 2021 → Dec 2022 | hematopoietic and lymphoid cell neoplasm | Nelson Chao | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT02669251 | Apr 2016 → Dec 2027 expected | bronchiolitis obliterans syndrome, chronic graft versus host disease | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT02597101 | Nov 2015 → Jun 2019 | type 2 diabetes mellitus | Nick Giannoukakis, PhD | Completed | No outcome recorded |
| Phase 2 | NCT01054170 | Jan → Nov 2010 | chronic obstructive pulmonary disease | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT01023516 | Nov 2009 → Aug 2010 | chronic obstructive pulmonary disease | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00757848 | Oct 2008 → Aug 2009 | cystic fibrosis | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00769119 | Sep 2008 → Apr 2009 | bronchiectasis | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00703391 | Jun → Sep 2008 | chronic obstructive pulmonary disease | AstraZeneca | Completed | No outcome recorded |
Also used as a comparator or background therapy in 4 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04539795 Comparator | Jan → Oct 2021 | COVID-19 | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT03679598 Comparator | Apr 2019 → Nov 2023 | alpha 1-antitrypsin deficiency, chronic obstructive pulmonary disease | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 2 | NCT03636347 Comparator | Oct 2018 → Mar 2022 | alpha 1-antitrypsin deficiency, pulmonary emphysema | Mereo BioPharma | Completed | No outcome recorded |
| Phase 2 | NCT00949975 Comparator | Jul 2009 → Aug 2010 | chronic obstructive pulmonary disease | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 19 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Alvelestat | “Alvelestat (MPH966) (Formerly known as AZD9668) is a potent and selective inhibitor of NE” NCT02669251 ↗ |
| Known as | AZD9668 | “Alvelestat (MPH966, formerly AZD9668) is a potent, selective, and reversible, oral inhibitor of human NE.” NCT03679598 ↗13“Alvelestat (MPH966) (Formerly known as AZD9668) is a potent and selective inhibitor of NE” NCT02669251 ↗ |
| Known as | MPH966 | “Alvelestat (MPH966, formerly AZD9668) is a potent, selective, and reversible, oral inhibitor of human NE.” NCT03679598 ↗2“Alvelestat (MPH966) (Formerly known as AZD9668) is a potent and selective inhibitor of NE” NCT02669251 ↗ |
| Action | Inhibit | “neutrophil elastase inhibitor AZD9668” PMID 22267768 ↗ Jan 20121“Leukocyte elastase inhibitor” CHEMBL3617964 ↗ |
| Modality | Small molecule | — CHEMBL3617964 ↗ |
| Route | Oral | “30mg oral tablets twice daily (bid) for 14 days” NCT00703391 ↗ |
| Target | ELANE | “Leukocyte elastase inhibitor” CHEMBL3617964 ↗ |